1. Home
  2. ASRT vs XFOR Comparison

ASRT vs XFOR Comparison

Compare ASRT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASRT
  • XFOR
  • Stock Information
  • Founded
  • ASRT 1995
  • XFOR 2014
  • Country
  • ASRT United States
  • XFOR United States
  • Employees
  • ASRT N/A
  • XFOR N/A
  • Industry
  • ASRT Biotechnology: Pharmaceutical Preparations
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ASRT Health Care
  • XFOR Health Care
  • Exchange
  • ASRT Nasdaq
  • XFOR Nasdaq
  • Market Cap
  • ASRT 79.1M
  • XFOR 84.3M
  • IPO Year
  • ASRT 1997
  • XFOR N/A
  • Fundamental
  • Price
  • ASRT $0.80
  • XFOR $3.50
  • Analyst Decision
  • ASRT Strong Buy
  • XFOR Strong Buy
  • Analyst Count
  • ASRT 1
  • XFOR 3
  • Target Price
  • ASRT $3.00
  • XFOR $34.17
  • AVG Volume (30 Days)
  • ASRT 265.0K
  • XFOR 10.7M
  • Earning Date
  • ASRT 08-11-2025
  • XFOR 08-08-2025
  • Dividend Yield
  • ASRT N/A
  • XFOR N/A
  • EPS Growth
  • ASRT N/A
  • XFOR N/A
  • EPS
  • ASRT N/A
  • XFOR N/A
  • Revenue
  • ASRT $117,099,000.00
  • XFOR $32,774,000.00
  • Revenue This Year
  • ASRT N/A
  • XFOR $1,313.84
  • Revenue Next Year
  • ASRT $5.84
  • XFOR N/A
  • P/E Ratio
  • ASRT N/A
  • XFOR N/A
  • Revenue Growth
  • ASRT N/A
  • XFOR 5721.31
  • 52 Week Low
  • ASRT $0.51
  • XFOR $1.35
  • 52 Week High
  • ASRT $1.38
  • XFOR $26.83
  • Technical
  • Relative Strength Index (RSI)
  • ASRT 54.77
  • XFOR 55.98
  • Support Level
  • ASRT $0.78
  • XFOR $3.02
  • Resistance Level
  • ASRT $0.87
  • XFOR $3.79
  • Average True Range (ATR)
  • ASRT 0.03
  • XFOR 0.59
  • MACD
  • ASRT -0.00
  • XFOR -0.03
  • Stochastic Oscillator
  • ASRT 34.36
  • XFOR 44.12

About ASRT Assertio Holdings Inc.

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Share on Social Networks: